Vogenx (NASDAQ:VOGX) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Vogenx (NASDAQ:VOGX) to a hold rating in a report published on Saturday morning.

Vogenx Trading Up 24.8%

VOGX stock opened at $29.52 on Friday. Vogenx has a 12-month low of $12.95 and a 12-month high of $29.64.

About Vogenx

Vogenx Inc is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc is based in RALEIGH, NC.